Importance of bone turnover for therapeutic decisions in patients with CKD-MBD

Susan M. Ott, Hartmut H. Malluche, Vanda Jorgetti, Grahame J. Elder

Research output: Contribution to journalComment/debate

9 Scopus citations


Patients with chronic kidney disease–mineral and bone disorder (CKD-MBD) frequently have low bone formation rates. A recent review suggested that adynamic bone disease is not always associated with negative outcomes and therefore antiresorptive medications could be used more often. However, there is currently no evidence to support an improvement in fracture risk or mortality in patients with CKD-MBD and low bone turnover who are treated with antiresorptive medication. There is reasonable pathophysiological evidence suggesting that it may even be harmful.

Original languageEnglish
Pages (from-to)502-505
Number of pages4
JournalKidney International
Issue number3
StatePublished - Sep 2021

Bibliographical note

Publisher Copyright:
© 2021 International Society of Nephrology

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Importance of bone turnover for therapeutic decisions in patients with CKD-MBD'. Together they form a unique fingerprint.

Cite this